baber/WOPTO huggingface dataset:
Patent NZ-330787-A (NZ)
Title: New chromene compounds that bind selectively to d3 dopaminergic receptors
Inventor: LAVIELLE GILBERT
IPC: C07D491/052
Filed: 1998-06-23
Abstract: Hexahydro-chromeno-Ä3,4-cÜ-pyrrole derivatives of formula (I), their enantiomers, diastereoisomers and salts are new. m = 0-3; n = 0-3; n+m = 2 or 3; p = 1-6; the junction between rings B and C is trans; X = CN or -CONR4R5; R4, R5 = H, 1-6C alkyl, 3-7C cycloalkyl or optionally substituted aryl; A = sigma bond or -NR-CO-, -CO-NR-, -NR-SO2-, or -SO2-NR-; R = H or 1-6C alkyl; R1, R2 = H or 1-6C alkyl; R3 = H or phenyl, naphthyl or heteroaryl (all optionally substituted by one or more halo, 1-6C alkyl or alkoxy, OH, CN, NH2, NO2, COOH, 1-6C perhaloalkyl, sulphonyl, acylamino, 1-6C alkylsulphonyl, or 1-6C alkyl sulphonylamino), aryl or heteroaryl (both substituted by A'-Cy), 2-indolinon-5-yl, or, when A is a sigma bond, aryloxy or arylthio; A' = sigma bond or 1-6C alkylene or alkenylene, (in which one C atom may be replaced by O or S), -NR-CO-, -CO-NR-, -NR-SO2-, or -SO2-NR-; Cy = aryl or heteroaryl (optionally substituted); provided that when n = 0, then m is other than 2, when n = 1, R1, R2 = H, A = sigma bond and p = 1, then R3 is not phenyl nor pyridyl, when n = 1, R1 & R2 = H, A = sigma bond, R3 is not H, when n = 1, R1 & R2 = H, A = -NH-CO-, then R3 is other than H, phenyl, naphthyl, thienyl, furyl, pyrrolyl, pyridyl, (all optionally substituted by one or more halo, trihalomethyl, alkoxy or OH).
Patent NZ-500015-A (NZ)
Title: Synthetic peptides useful in biological assays for detecting infections caused by group O HIV-1 viruses
Inventor: DELAGNEAU JEAN-FRANCOIS HUBERT
IPC: A61K38/16
Filed: 1998-04-06
Abstract: Peptides used in biological assays for detecting infections caused by group O HIV-1 viruses, compositions and kits containing such peptides and the biological assays using such peptides.
Patent NZ-503637-A (NZ)
Title: Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids and their use as matrix metalloproteinase and TACE inhibitors
Inventor: LEVIN JEREMY IAN
IPC: A61K31/437
Filed: 1998-04-14
Abstract: Low molecular weight, non-peptide inhibitors of matrix metalloproteinases and TNF- alpha converting enzyme (TACE, tumour necrosis factor- alpha converting enzyme) of formula (B) wherein (B) is (1), (2), or (3); P and Q are (4) or (5), provided that when P is (4), Q is (5), and vice versa; T, U, W, and X are each, independently, carbon or nitrogen, provided that when T or U is carbon, either may be optionally substituted with R1; Y is carbon, nitrogen, oxygen or sulphur, provided that at least one of T, U, W, X, and Y is not carbon, and further provided that no more than 2 of T, U, W, and X are nitrogen; (6) is a phenyl ring or is a heteroaryl ring of ring 5-6 atoms which may contain 0-2 heteroatoms selected from nitrogen, oxygen, and sulphur, in addition to any heteroatoms defined by W or X; wherein the phenyl or heteroaryl ring may be optionally mono-, di-, or tri- substituted with R1; Z is a phenyl, naphthyl, heteroaryl, or heteroaryl fused to phenyl, wherein the heteroaryl moiety contains of 5-6 ring atoms and 1-3 heteroatoms selected from nitrogen, oxygen, or sulphur; wherein the phenyl, naphthyl, heteroaryl, or phenyl fused heteroaryl moieties may be optionally mono-, di-, or tri-substituted with R1; R1 is hydrogen, halogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cyclocalkyl of 3-6 carbon atoms, -(CH2)nZ, -OR2, -CN, -COR2, perfluoroalkyl of 1-4 carbon atoms, -CONR2R3, -S(O)xR2-OPO(OR2)OR3, -PO(OR2)R3, -OC(O)NR2R3, -COOR2, -CONR2R3, -SO3H, -NR2R3, -NR2COR3, -NR2COOR3, -SO2NR2R3, -NR2CONR2R3, -NR2C(=NR3)NR2R3, -SO2NHCOR4, -CONHSO2R4, -tetrazol-5-yl, -SO2NHCN, -SO2NHCONR2R3, or Z; V is a saturated or partially unsaturated heterocycloalkyl ring of 5-7 ring atoms having 1-3 heteroatoms selected from N, O, or S, which may be optionally mono-, or di-substituted with R2; R2 and R3 are each, independently, hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R4 is alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, cycloalkyl of 3-6 carbon atoms; perfluoroalkyl of 1-4 carbon atoms, Z or V; R5 is hydrogen, alkyl of 1-8 carbon atoms, alkenyl of 2-6 carbon atoms, alkynyl of 2-6 carbon atoms, Z, or V; n = 1-6; x = 0-2 or a pharmaceutically acceptable salt thereof.
Patent NZ-506759-A (NZ)
Title: Container for a medicinal liquid
Inventor: KLADDERS HEINRICH
IPC: B65D83/14
Filed: 1999-02-26
Abstract: According to the invention, film bags are used as primary packaging for liquids and permit the liquid to be withdrawn without considerable exertion of force. The invention provides a container for a medicinal liquid which is both gas and liquid tight and which can be stored for many months. The container is comprised of a collapsible film on which a dimensionally stable flange (12) is attached. The flange is designed so that it can be attached onto a dispensing support (not shown). The container can be situated in a dimensionally stable sleeve (not shown). The medicinal liquid does not come in contact with air and is protected against the effects of light. The medicinal liquid can be withdrawn from the film bag, for example, in many partial quantities over a long period of time, whereby each partial quantity is reduced into an aerosol by means of an atomizer.
Patent NZ-510709-A (NZ)
Title: Helmet with segemented peripheral panels and an armature
Inventor: WITHNALL CHRISTOPHER ROBERT PA
IPC: A42B3/00
Filed: 1999-09-24
Abstract: A comfortable, self-adjusting, protective helmet made from a process of insert moulding. The helmet comprises an armature or insert made of a porous material that is embedded in the layers of the helmet to connect the structural parts of the helmet to one another. The armature as used in the helmet also serves several other functions which include hinging and sizing. A retention system is strategically located on the helmet to provide increased stabilization of the helmet on the wearer's head. One embodiment of this invention is an insert-moulded helmet that can be converted into a pouch. A further embodiment of this invention includes a protrusion at the back of a helmet suitable for a compartment
Patent NZ-510832-A (NZ)
Title: A block copolymer with a high total weight percentage of hydrophobic polyester A-block relative to the hydrophilic PEG B-block that is water soluble below room temperature
Inventor: RATHI RAMESH C
IPC: A61K38/095
Filed: 1999-09-30
Abstract: A water soluble, biodegradable ABA- or BAB-type tri-block polymer is disclosed that is made up of a major amount (51-83%) of a hydrophobic A polymer block made of a biodegradable polyester and a minor amount (17-49%) of a hydrophilic polyethylene glycol (PEG) B polymer block, having an overall average molecular weight of between about 2000 and 4990, and that possesses reverse thermal gelation properties. Effective concentrations of the tri-block polymer and a drug may be uniformly contained in an aqueous phase to form a drug delivery composition.  At temperatures below the gelation temperature of the tri-block polymer the composition is a liquid and at temperatures at or above the gelation temperature the composition is a gel or semi-solid.  The composition may be administered to a warm-blooded animal as a liquid by parenteral, ocular, topical, inhalation, transdermal, vaginal, transurethral, rectal, nasal, oral, pulmonary or aural delivery means and is a gel at body temperature.  The composition may also be administered as a gel. The drug is released at a controlled rate from the gel which biodegrades into non-toxic products. The release rate of the drug may be adjusted by changing various parameters such as hydrophobic/hydrophilic component content, polymer concentration, molecular weight and polydispersity of the tri-block polymer.  Because the tri-block polymer is amphiphilic, it functions to increase the solubility and/or stability of drugs in the composition.
Patent NZ-515297-A (NZ)
Title: Energy-activated compositions for controlled sustained release of a gas
Inventor: WELLINGHOFF STEPHEN T
IPC: C01B7/01
Filed: 2000-04-20
Abstract: A composition for energy-controlled generation and release of at least one gas, which includes an energy-activated catalyst capable of being activated by electromagnetic energy, and a solid or a liquid containing anions capable of being oxidized by the activated catalyst or reacted with species generated during activation of the catalyst to generate at least one gas. The composition, when exposed to electromagnetic energy, is capable of generating and releasing the gas after activation of the catalyst and oxidation or reaction of the anions.
Patent NZ-523887-A (NZ)
Title: Velocity sequencing of polymeric DNA in electrophoretic apparatus
Inventor: SIDERIS DIMITROIS
IPC: G01N27/447
Filed: 2001-07-20
Abstract: A space-time map M of points representative of the signal peaks of signals detected at a plurality of positions as passed by the migrating components of a plurality of separately provided plugs of DNA in an electrophoretic experiment is generated and a set of vertices VA, VT, VG, VC is identified from the spaceûtime map.  A single vertex is identified for the components of each separately provided sample plug and the sample velocities of the sample components are determined from the points in the space-time map.
Patent NZ-531720-A (NZ)
Title: Bioreactors comprising cultured liver cells suitable for use as an artificial liver
Inventor: REID LOLA M
IPC: A61K35/12
Filed: 2004-03-12
Abstract: A bioreactor comprising a composition of an enriched population of human liver progenitors their progeny, or more mature forms of said human liver progenitors which exhibit one or more markers indicative of expression of full-length alpha-fetoprotein, full length albumin or both and at least one compartment having culture medium. Such a bioreactor is particularly useful as an artificial liver.
Patent NZ-531911-A (NZ)
Title: Pyrimidinones as melanin concentrating hormone receptor 1
Inventor: CARPENTER ANDREW J
IPC: A61K31/517
Filed: 2002-10-15
Abstract: A compound of formula (Ia) is disclosed intended for the treatment of diseases such as diabetes, hypertension, depression, anxiety, obesity and arteriosclerosis. A process for the preparation of a compound of formula (Ia) is also disclosed.
Patent NZ-532159-A (NZ)
Title: [[2-(amino-3,4-dioxo-1-cyclobuten-1-yl)amino]alkyl]-acid derivatives for the treatment of pain
Inventor: BRANDT MICHAEL RICHARD
IPC: A61K31/66
Filed: 2002-10-09
Abstract: Use of a compound having the formula (I) in the preparation of a medicament for the treatment of pain, including inflammatory and neuropathic pain, in a mammal is disclosed. R1 is hydrogen, alkyl of 1 to 6 carbon atoms or phenylalkyl of 7 to 12 carbon atoms; R2 is hydrogen, alkyl of 1 to 6 carbon atoms, alkenyl of 2 to 6 carbon atoms or phenylalkyl of 7 to 12 carbon atoms; or R1 and R2 taken together as Z are-CH2CH2-, -CH2C(R6)(R7)CH2- or -CH2C(R8)(R9)-C(R10)(R11)CH2-, where R6, R8 and R10 are, independently, hydrogen, alkyl of 1 to 6 carbon atoms or hydroxyl and R7,R9 and R11 are, independently, hydrogen or alkyl of 1 to 6 carbon atoms; A is alkylene of 1 to 6 carbon atoms or alkenylene of 2 to 6 carbon atoms; and X is CO2R3, P(O)(OR4)(OR5), 3,5-dioxo-1,2,4-oxadiazolidin-2-yl or 5-tetrazolyl. Also disclosed is the use of a compound described above in conjunction with a pain relieving agent such as analgesics and anti-inflammatory agents
Patent NZ-532894-A (NZ)
Title: Retroviral vectors including modified envelope escort proteins
Inventor: HALL FREDERICK L
IPC: A61K48/00
Filed: 1999-04-28
Abstract: A retroviral vector comprising a first retroviral envelope protein and at least one modified retroviral envelope protein, wherein said first retroviral envelope protein includes a surface protein comprising (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion being the remaining C-terminus of the surface protein, and said modified retroviral envelope protein, prior to modification, includes a surface protein which includes (i) a receptor binding region; (ii) a hypervariable polyproline region; and (iii) a body portion being the remaining C-terminus of the surface protein, wherein said modified retroviral envelope protein has been modified such that at least 90% of the amino acid residues of the receptor binding region of said surface protein of said modified retroviral envelope protein are removed or replace with a non-retroviral protein or polypeptide which is a ligand which binds to an extracellular matrix component, is a complement regulatory protein or is selected form the group consisting of Protein A, Protein ZZ and VEGF.
Patent NZ-532970-A (NZ)
Title: System and method for traffic channel dormancy in wireless communication socket mode
Inventor: LINDNER MARK
IPC: H04J13/00
Filed: 2002-11-22
Abstract: In a wireless communication system such as a CDMA system, a traffic channel supporting two applications running in socket mode on a mobile station is allowed to go dormant and is released when respective idle periods associated with each socket expire, that is, when there is no transmission over the traffic channel for the longer of two potentially unequal idle periods. Alternatively, all of the applications associated with the traffic channel are determined, and the traffic channel associated with those applications is enabled to be released only when all of the associated applications do not require the channel.
Patent NZ-533571-A (NZ)
Title: Blind fastener with a blind side head having a clamp support and lock section
Inventor: TERRY WILLIAM W
IPC: F16B1/00
Filed: 2002-12-04
Abstract: A two piece blind fastener (10) for securing a plurality of workpieces (20, 22) including a hollow sleeve (12) having an enlarged sleeve head (26) at one end and a pin (14) having an enlarged shear ring (46) at the end opposite the sleeve head followed by an elongated retention portion (48) of reduced diameter. The shear ring is adapted to engage and move inside the sleeve to form a tuliped shaped blind head in response to a relative axial force applied between the pin and sleeve and to shear off proximate to the inner or blind sheet line (64) of the workpieces. The retention portion is then moved with the pin shank (40) into the shear ring and with the shear ring finally located at a position on the retention portion depending upon the overall thickness of the workpieces. This provides a clamp and lock section between the pin and sleeve at the inner or blind side of the workpieces. The pin and sleeve have a lock structure actuated after final formation of the clamp and lock section to provide a lock between the pin and sleeve.
Patent NZ-534151-A (NZ)
Title: A process of purification of an otherwise pure nona- or decapeptide from residual organic solvent
Inventor: RASMUSSEN PALLE H
IPC: C07K7/06
Filed: 2002-12-23
Abstract: A nona- or decapeptide is purified from residual organic solvent by dissolving in a solvent comprising water and at least one C1-C3 alcohol followed by precipitation into a vigorously stirred solvent consisting of an alkyl ester of a carboxylic acid, the ester comprising from 3 to 6 carbon atoms, and one or several non-polar compounds selected from hexane, heptane, octane, cyclohexane, methylcyclohexane, and, optionally, of up to 5 % of acetic or propionic acid, isolating the precipitated nona- or decapeptide, followed by washing with a mixture of C3-C5 esters and drying, wiht the provisio that the water content of the solvent comprising water and the at least one alcohol is below 8 % (v/v), and that the volume ratio of the dissolution solvent mixture and the precipitation solvent mixture is 1:10 or higher. Also described is the monoacetate of Ac-D-2Nal-D-4ClPhe-D-3Pal-Ser-MeTyr-D-Asn-Leu-Lys(iPr)-Pro-D-Ala-NH2.
Patent NZ-535415-A (NZ)
Title: Dimmer circuit with improved inductive load imbalance protection
Inventor: VANDERZON JAMES ROBERT
IPC: H05B47/10
Filed: 2003-03-25
Abstract: A protection circuit is disclosed for protecting a dimmer circuit that controls an inductive load. The protection circuit includes a load imbalance detector for detecting an asymmetrical operation in the load, and circuit control means for causing the dimmer circuit to reduce a DC component in the load upon detection of the asymmetrical operation. The load imbalance detector includes a load DC component detector that detects a DC component in the inductive load, a comparator for comparing a magnitude of the DC component detected by the load DC component detector with a reference voltage, and a signal generator for generating a circuit shutdown signal if the DC component exceeds a pre-set DC voltage threshold.
Patent NZ-540174-A (NZ)
Title: System and method for managing and communicating software updates to a client computer from a software update service
Inventor: AVERBUCH AARON H
IPC: G06F9/445
Filed: 2004-07-23
Abstract: In a computer system including a client computing device in communication with a software update service, a method for communicating software updates from the software update service to the client computing device is disclosed. The method comprises: A synchronization request from the client computing device to the software update service is obtained. The synchronization request includes an identifier of an installed software update if the client computing device stores the installed software update. The software update service determines if the synchronization request comprises an identifier of at least one installed software update. If it is determined that the synchronization request comprises an identifier of at least one installed software update then an additional software update for communication to the client computing device is then selected. The selection of the additional software update is dependent on the fulfilling at least a first prerequisite defined in the additional software update. The first prerequisite requires the synchronization request to include an identifier for at least one installed software update. If it is determined that the synchronization request does not comprise an identifier of at least one installed software update a first level software update for communication to the client computing device is then selected. The first level software update does not include a prerequisite. An instruction component of the selected software update to the client computing device is communicated from the software update service. The instruction components of the selected software update is stored in the client computing device as an installed software update if the client computing device contains at least one component that fulfils all conditions of any applicability rule stored in the instruction component of the selected software update. The instruction components of the selected software update is stored in the client computing device as a failed software update if the client computing device does not contain at least one component that fulfils at least one condition of an applicability rule stored in the instruction component of the selected software update. A localised data component of the selected software update from the software update service is communicated to the client computing device if the instruction component does not provide an indication that the software update service contains additional software updates available to the client computing device.
Patent NZ-540617-A (NZ)
Title: Food additive composition made from natural products which assists retention of the characteristics of the baked or fried foods to which it has been added, cooled and subsequently heated in a microwave oven
Inventor: FRANKLIN BRIAN JOHN
IPC: A23L7/157
Filed: 2003-12-12
Abstract: A food additive composition is described, comprising i) a bean powder, especially lima bean powder, ii) water absorbent vegetable fibre, iii) one or more inorganic calcium compounds, and iv) modified cellulose wherein the bean powder i) is present in a proportion of between 50 and 90% by weight based on the total weight of i), ii), iii) and iv). Foods comprising the additive composition, which are cooked or reheated in a microwave oven, have generally improved characteristics such as taste and texture as compared with similar foods not comprising the additive.
Patent NZ-543771-A (NZ)
Title: Acapsular Pasteurella multocida hyae deletion mutants
Inventor: BRIGGS ROBERT E
IPC: A61K39/102
Filed: 2004-07-02
Abstract: A capsular hyaE deletion mutants of Pasteurella multocida can be administered to mammals, particularly ungulates, or birds to provide protective immunity against wild-type Pasteurella multocida, e.g., to prevent or reduce the severity of hemorrhagic septicemia or pneumonia in mammals, particularly livestock, ungulates, and companion animals, or fowl cholera in birds, particularly poultry.
Patent NZ-544221-A (NZ)
Title: Pyrido[2,1-a]-isoquinoline derivatives as DPP-IV inhibitors
Inventor: BOEHRINGER MARKUS
IPC: C07D471/04
Filed: 2004-06-11
Abstract: Disclosed are compounds of formula (I) wherein R1, R2, R3 and R4 are as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prophylaxis of diseases which are associated with DPP-IV, such as diabetes, particularly non-insulin dependent diabetes mellitus and impaired glucose tolerance. Also disclosed are a process for the manufacture of compounds of formula (I) and pharmaceutical compositions comprising the compounds.
Patent NZ-547103-A (NZ)
Title: Use of desoxypeganine for the treatment of schizophrenic psychoses
Inventor: MOORMANN JOACHIM
IPC: A61K31/33
Filed: 2004-11-08
Abstract: Disclosed is the use of deoxypeganine, in the form of a free base or in the form of an acid addition salt, or of a derivative of deoxypeganine as long as said derivative is simultaneously an inhibitor of acetylcholinesterase and of monoamine oxidase, for producing a medicament for treating a schizophrenic psychosis which is connected with increased monoamine oxidase activity and/or decreased functionality (decreased activity or decreased expression) of nicotinic acetylcholine receptors.
Patent NZ-547378-A (NZ)
Title: Method for the treatment and long-term preservation of meat products without a cold chain using brine, cooking, freezing and irradiation
Inventor: CURUTCHET FERREIRA PABLO ROMAN
IPC: A23B4/005
Filed: 2004-12-07
Abstract: Discloses is a method for the treatment and long-term preservation of meat products without a cold chain, including the steps of selecting and cutting meat into meat cuts or pieces , cutting up the meat pieces , if necessary , f or removing fat and minor portions thereof , to obtain pieces having a size and weight within a uniform range , the process being characterized by the following steps : a) Injecting each piece of meat with a brine solution containing NaC1 in at least a concentration to reach a maximum of 20% of the weight of the injected piece of meat ; b) Once all the pieces of meat within a batch have been injected the meat is massaged for a period of time of within 8 to 24 hours under a reduced pressure of between 10 and 15" HG and a reduced temperature of between O°C and 3°C ; c) Removing the batch from the massage machine and introducing each piece of meat into a sealed bag made of an impervious polymer , and subjecting the bagged meat to a cooking process in hot water until reaching a temperature of 70°c to 85'C measured i n the core of the biggest piece of meat for a time of 15 to 30 minutes ; d) Removing the bags with the meat from the cooking water, removing the meat from each bag and cooling the meat until reaching a temperature of about 26°C measured in the geometrical centre of the pieces of meat ; e) Once the cooling step has finished, packaging each pre-cooked piece of meat in other bags apt for vacuum packaging ; f) Freezing the pieces of meat already conditioned to a temperature of about - 14 °C; g) Subjecting the al ready packaged and frozen pieces of meat to an irradiation process until cumulating a minimum total dose of 15 kGy.